iifl-logo-icon 1

KDL Biotech Ltd Share Price

2.1
(-4.55%)
Dec 5, 2013|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

KDL Biotech Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

2.1

Prev. Close

2.2

Turnover(Lac.)

0.01

Day's High

2.1

Day's Low

2.1

52 Week's High

0

52 Week's Low

0

Book Value

-35.74

Face Value

10

Mkt Cap (₹ Cr.)

5.05

P/E

0

EPS

0

Divi. Yield

0

KDL Biotech Ltd Corporate Action

No Record Found

KDL Biotech Ltd NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

KDL Biotech Ltd SHAREHOLDING SNAPSHOT

24 Aug, 2024|09:44 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 23.46%

Foreign: 23.46%

Indian: 45.39%

Non-Promoter- 2.46%

Institutions: 2.46%

Non-Institutions: 28.67%

Custodian: 0.00%

Share Price

KDL Biotech Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2012Mar-2011Mar-2010

Equity Capital

24.04

24.04

24.04

Preference Capital

0

0

0

Reserves

-83.21

-66

-1.69

Net Worth

-59.17

-41.96

22.35

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2012Mar-2011

Revenue

26.46

28.4

yoy growth (%)

-6.83

Raw materials

-4.7

-7.81

As % of sales

17.76

27.51

Employee costs

-9.64

-9.35

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2012Mar-2011

Profit before tax

-17.21

-45.12

Depreciation

-9.13

-22.34

Tax paid

0

-7.69

Working capital

-7.93

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2012Mar-2011

Growth matrix (%)

Revenue growth

-6.83

Op profit growth

-87.36

EBIT growth

-72.79

Net profit growth

-73.23

View Ratios

No Record Found

KDL Biotech Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,775.75

150.914,20,027.58237.820.774,409.7498.75

Divis Laboratories Ltd

DIVISLAB

4,855.95

78.491,30,370.294300.612,063507.93

Cipla Ltd

CIPLA

1,574.55

32.241,28,058.811,055.940.823,752.25346.4

Zydus Lifesciences Ltd

ZYDUSLIFE

1,178.7

27.871,21,729.161,700.80.254,035.4156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,954.5

28.241,16,346.951,417.20.575,823.91,458.7

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT KDL Biotech Ltd

Management

Register Office

Registrar Office

Managing Director

Nalin Bamzai

Director (Technical)

Rajesh Agrawal

Director

Sanjay Sinha

Director

Yogendra Kumar Chauhan

Company Secretary

Manish Bhojwani

Additional Director

Avantika Varma

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Promoted by the Parijat Enterprises, Kopran is currently an integrated health care company. The company has used research-based technology to contribute towards total health-care. From diagnostics to treatment, speciality bulks to finished dosage forms, bio-technology to sophisticated and medical electronic equipments maintaining quality on par with the best in the world, and thereby vying for brand equity in the global context.The companys major foray into the business of biotechnology based products its name is changed from Kopran Drugs to KDL Biotech (KDL).The company started modestly as a Semi Synthetic Penicillin (SSP) player and expanded to becomes the largest SSP Player in India with an annual SSP facility of over 1200 TPA. Subsequently the SSP business was hived off into a separate Company in a joint venture with Synpac Pharmaceuticals Ltd, UK.Its is growing with a vision to focus on Brand Equity Development, Research for New Chemical Entities and globalise its operations thus making KDL a truly International Pharmaceutical Company.
Read More

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020
  • Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
  • Pay 20% upfront margin of the transaction value to trade in cash market segment.
  • Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.
  • Check your Securities / MF / Bonds in the consolidated account statement issued by NSDL/CDSL every month.
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp